Last updated 11 months ago
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
372 patients around the world
Available in Spain, United States, Chile
Bristol-Myers Squibb
372Patients around the world
This study is for people with
Advanced tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1At least 1 lesion accessible for biopsyEastern Cooperative Oncology Group Performance Status of 0 or 1
- Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)Participants with active, known or suspected autoimmune diseaseParticipants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administrationParticipants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
SponsorBristol-Myers Squibb
Conditions
Advanced tumors
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT03400332
